Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Zevra Therapeutics, Inc. - Common Stock (NQ: ZVRA ) 6.230 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 910 Open 6.230 Bid (Size) 6.150 (1) Ask (Size) 6.230 (1) Prev. Close 6.230 Today's Range 6.230 - 6.230 52wk Range 3.890 - 7.280 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 10 Health Care Stocks Whale Activity In Today's Session July 23, 2024 Via Benzinga Insiders Buying Zevra Therapeutics And 1 Other Stock July 18, 2024 Via Benzinga Performance YTD -8.78% -8.78% 1 Month +35.73% +35.73% 3 Month +37.83% +37.83% 6 Month +6.13% +6.13% 1 Year +32.27% +32.27% More News Read More Insiders Buying Barnes & Noble Education And 2 Other Stocks July 17, 2024 Via Benzinga SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL July 11, 2024 Via AB Newswire FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base July 09, 2024 Via Benzinga Exposures Product Safety Zevra Therapeutics: Q4 Earnings Insights March 28, 2024 Via Benzinga Earnings Outlook For Zevra Therapeutics March 27, 2024 Via Benzinga Zevra Therapeutics's Earnings: A Preview November 06, 2023 Via Benzinga Zevra Therapeutics's Earnings: A Preview August 11, 2023 Via Benzinga ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 08, 2024 Via InvestorPlace Zevra Therapeutics, Inc. (NASDAQ: ZVRA) Letter to Stakeholders Looks Like Launch Code to Drive Value May 06, 2024 Via Investor Brand Network ZEVRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zevra Therapeutics, Inc. on Behalf of Zevra Stockholders and Encourages Investors to Contact the Firm April 03, 2024 From Bragar Eagel & Squire Via GlobeNewswire Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zevra Therapeutics, Inc. (ZVRA) April 02, 2024 From Kirby McInerney LLP Via GlobeNewswire ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023 March 28, 2024 Via InvestorPlace Earnings Scheduled For March 28, 2024 March 28, 2024 Via Benzinga Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday December 28, 2023 Via Benzinga BioMedNewsBreaks – Zevra Therapeutics Inc. (NASDAQ: ZVRA) Resubmits Arimoclomol New Drug Application to the FDA December 27, 2023 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks — Zevra Therapeutics Inc. (NASDAQ: ZVRA) Names New President, CEO and Director October 10, 2023 Via Investor Brand Network Topics Retirement Exposures Pension Earnings Scheduled For November 7, 2023 November 07, 2023 Via Benzinga Health Care Company Zevra Therapeutics Announces Merger With Acer Therapeutics August 31, 2023 Via Benzinga Why Is Acer Therapeutics Stock Trading Higher Today? August 31, 2023 Via Benzinga BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - August 31, 2023 From Brodsky & Smith LLC Via GlobeNewswire Why Is Acer Therapeutics (ACER) Stock Up 85% Today? August 31, 2023 Via InvestorPlace Earnings Scheduled For August 14, 2023 August 14, 2023 Via Benzinga Earnings Scheduled For May 15, 2023 May 15, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
